Positive adjusted EBITDA in Q4 2025 , which they highlighted as proof of a new cost structureManagement said that about a year earlier it began transforming the business by divesting its desktop products, citing headwinds in the academic and biopharma markets. The company said this move helped it “secure” its balance sheet, reset its cost structure, and “double down” on growth areas tied to public safety, security, and defense.In the presentation, the company reported more than 3,700 devices deployed across ...

Summary of 908 Devices Conference Call Company Overview - **Company**: 908 Devices (NasdaqGM:MASS) - **Industry**: Analytical technology for public health, safety, and defense applications - **Products**: Handheld and portable analytical tools for chemical detection Key Points Business Transformation and Growth - 908 Devices is at an inflection point, having undergone a transformation by divesting desktop products and focusing on growth areas, resulting in a more secure balance sheet and improved cost structure [2][3] - The company achieved an 18% year-over-year growth in 2025, with positive adjusted EBITDA in Q4 and a cash balance of $113 million [4][13] - The installed base of devices increased to over 3,700, a 54% increase since year-end 2023 [12] Product Innovations - The flagship product, MX908, is a handheld mass spectrometer that has seen over 3,100 units deployed [5] - New products like XplorIR and VipIR are driving growth, with VipIR expected to be a significant contributor in 2026 [7][18] - In 2025, 50% of device placements were beyond the core mass spec, indicating diversification in product offerings [6] Market Demand and Trends - The opioid crisis and rising defense budgets are key secular tailwinds for the company, with increasing demand for modern detection tools [4][10] - The company is addressing urgent public health threats, including synthetic drugs and hazardous VOCs, which are becoming significant risks for frontline responders [8][9] Financial Projections - Projected revenue growth for 2026 is between 15%-20%, with expectations for further adjusted gross margin expansion [14][32] - The company aims to cut adjusted EBITDA losses in half year-over-year, targeting mid-single-digit millions [15] Recurring Revenue Model - Recurring revenue accounted for 35% of total revenues in 2025, with plans to maintain this level as it provides predictable income [6][49] - The recurring revenue model includes service offerings and software updates, enhancing customer commitment [47][48] Operational Efficiency - Manufacturing operations have been consolidated in Danbury, Connecticut, which is expected to improve margins and production capacity [27][28] - The company has not faced significant supply chain issues, primarily sourcing materials domestically [30] International Market Opportunities - Approximately 27% of revenues came from international markets, with growth expected due to increased NATO spending on equipment modernization [23][24] - The company has seen orders from countries like Poland and the Czech Republic, indicating a trend towards modernization in response to security threats [24][25] Strategic Partnerships - The AVCAD program with Smiths Detection is anticipated to generate $2 million-$3 million in revenue in 2026, representing a long-term growth opportunity [34][35] Future Outlook - The company is focused on maintaining a healthy balance sheet while investing in growth opportunities, including potential acquisitions [41][42] - The path to profitability is becoming clearer, with expectations for cash flow positivity in the coming years [38][39] Additional Insights - The unique integration of two optical technologies in the VipIR product is a competitive advantage, supported by patent protections [21][22] - The distribution model includes direct sales for state and local markets and partnerships for federal military sales, enhancing procurement efficiency [53][55]

Waters Prices Offering of Senior Notes Accessibility StatementSkip Navigation MILFORD, Mass., March 18, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) (the "Company" or "Waters") today announced that it has priced an offering (the "Offering") of $3.5 billion aggregate principal amount of the following senior notes issued by its subsidiary, Augusta SpinCo Corporation ("Augusta"): The Offering is expected to close on or about March 23, 2026, subject to the satisfaction of customary closing conditions. Th ...

Core Insights - Waters Corporation launched the ARES-G3 Rheometer, which sets a new benchmark for data quality and speed in materials research and product development [1] Product Features - The ARES-G3 Rheometer operates with fewer calibrations and superior atmosphere and temperature control [1] - It delivers an industry-leading 25,000 data points per second, which is 10 times more than its predecessor [1] - The device reduces standard testing times by up to 80%, with some tests being shortened from six hours to one [1] Industry Impact - The ARES-G3 Rheometer addresses significant industry limitations by enabling scientists to capture transient material behaviors that were previously undetectable [1] - It allows for increased lab throughput and the ability to perform many tests without requiring user calibrations, thus reducing human error [1] Technological Advancements - The integration of Fast Frequency Chirps and enhanced TRIOS Software simplifies data capture and processing, eliminating the need for multiple software licenses [1] - The new rheometer retains the best-in-class oven of the ARES-G2 Rheometer, providing leading low-oxygen atmosphere control and temperature uniformity [1] Compatibility and Availability - All existing ARES-G2 Rheometer methods and fixtures are fully compatible with the ARES-G3 Rheometer [1] - The ARES-G3 Rheometer is available for order immediately [1]

Core Insights - The company reported a fourth-quarter revenue of $17.4 million from continuing operations, reflecting a 21% year-over-year increase, primarily driven by strong demand for the XplorIR gas identification device and the new VipIR product [4][8] - The total number of devices shipped in the fourth quarter was 224, increasing the installed base to 3,736 [1][8] - Management provided guidance for 2026 revenue between $64.5 million and $67.5 million, indicating a growth rate of 15% to 20% compared to 2025 [6][17] Financial Performance - Handheld product and service revenue reached $16.0 million in the fourth quarter, up 18%, largely due to FTIR products [2] - The company achieved a positive adjusted EBITDA of $0.7 million, a significant improvement from a $4.0 million loss in the previous year [7][9] - Gross margin improved to 53%, with an adjusted gross margin of 57%, up approximately 530 basis points year-over-year [9] Operational Highlights - The company ended 2025 with $113 million in cash and marketable securities, with no outstanding debt [6][14] - Operating expenses decreased to $6.1 million in the fourth quarter, down from $23.4 million in the prior year, primarily due to the absence of non-cash charges [10] - The state and local sales channel revenue grew by 38% to approximately $24 million, representing 43% of total 2025 revenue [13] Product Developments - The VipIR product, launched in July 2025, combines FTIR and Raman spectroscopy with proprietary Smart Spectral Processing [18] - The next-generation MX platform is on track for a commercial launch later in 2026 [18] - The company consolidated U.S. federal contracting partners to improve procurement efficiency [15] Market Expansion - International revenue accounted for 27% of total revenue in 2025, up from 25% in 2024, with increased defense budgets among NATO countries [16] - The company is shipping chemical detection devices to various countries, including Poland and Ukraine [16] - Management emphasized the focus on scaling proven platforms and strengthening revenue durability through recurring revenue [20]

Financial Data and Key Metrics Changes - The company achieved $17.4 million in revenue from continuing operations in Q4 2025, representing a robust 21% year-over-year growth from $14.3 million in Q4 2024 [4][17] - For the full year 2025, revenue was $56.2 million, an 18% increase from $47.7 million in 2024, driven primarily by FTIR products [5][23] - Adjusted EBITDA for Q4 2025 was positive at $0.7 million, a significant improvement from a loss of $4 million in the prior year [5][22] - The company ended 2025 with $113 million in cash, with no debt outstanding, indicating a strong financial position [14][26] Business Line Data and Key Metrics Changes - Handheld product and service revenue was $16 million in Q4 2025, up 18% from $13.6 million in Q4 2024, driven by FTIR products [17] - Recurring revenue, which includes consumables, accessories, software, and service revenue, represented 32% of total revenues in Q4 2025, amounting to $5.5 million, an 11% increase year-over-year [19] - The XplorIR device achieved over 40% year-over-year growth, with more than 150 units delivered in its first full year of commercial sales [8][52] Market Data and Key Metrics Changes - 27% of revenues in 2025 came from international markets, an increase from 25% in 2024, with significant sales growth in NATO countries [10] - The company noted strong demand for its products in Europe, particularly due to increased defense budgets related to the ongoing war in Ukraine [10] Company Strategy and Development Direction - The company aims to scale proven platforms, extend platform leadership, and strengthen revenue durability as part of its strategic focus for 2026 [14][15] - The introduction of the VipIR device is expected to drive growth, with the company anticipating a full year of impact in 2026 [15][52] - The consolidation of contracting partners to one for U.S. federal government business is intended to improve procurement efficiency and forecasting accuracy [9][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to capitalize on growth opportunities driven by increased funding for public safety and defense [30] - The company expects revenue growth of 15%-20% in 2026, with guidance reflecting the anticipated impact of new products and market conditions [26][27] - Management highlighted the importance of their mission to protect frontline responders, emphasizing the societal value of their products [31] Other Important Information - The company reported a significant reduction in operating expenses for Q4 2025, totaling $6.1 million compared to $23.4 million in the prior year, largely due to non-cash items in 2024 [21] - The adjusted gross margin for the full year 2025 was 57%, an increase from 56% in 2024, driven by improved service and contract gross margins [25] Q&A Session Summary Question: Relationship with Mountain Horse - The company consolidated contracting partners to improve procurement efficiency and forecasting visibility, leveraging Mountain Horse's strong procurement relationships [33][36] Question: Next Gen MX908 Platform - The next-gen MX908 platform is on schedule for commercial launch in 2026, with expectations for significant demand due to its differentiated capabilities [41][42] Question: Growth Drivers for 2026 - Key growth drivers include the full-year impact of VipIR, continued demand for XplorIR, and increased defense spending due to global concerns [48][52] Question: Impact of Current Conflicts - Management does not foresee immediate disruptions from current conflicts but acknowledges potential increases in demand for their products [65][66] Question: Adjusted EBITDA Expectations - The company aims to cut its adjusted EBITDA loss in half for 2026, targeting low to mid-single-digit millions, while maintaining growth opportunities [59][60]

Financial Data and Key Metrics Changes - Agilent reported Q1 2026 revenue of $1.8 billion, growing 4.4% on a core basis, with a reported growth of 7% [5][24] - Operating margins were 24.6%, in line with expectations, and down 50 basis points year-over-year due to increased tariff expenses [6][26] - Q1 EPS was $1.36, reflecting a 4% growth, and adjusted for the weather impact, it would have exceeded the midpoint of guidance [6][26] Business Segment Data and Key Metrics Changes - ACG (Agilent CrossLab Group) grew 6%, driven by strong consumables growth and solid performance in services [24] - AMG (Applied Markets Group) grew 4%, led by double-digit performance in spectroscopy, particularly in the semiconductor space [24] - LDG (Life Sciences and Diagnostics Group) grew 3%, slightly below expectations due to weather impact and softness in academia and government [25][59] Market Data and Key Metrics Changes - Pharma growth was 7%, with double-digit growth in biotech, supported by increased funding and M&A activity [17] - The chemicals and advanced materials market grew 9%, with exceptional strength in materials, exceeding 20% growth [18] - The food business declined 4%, but performed better than expected, with strong growth outside of China [19] Company Strategy and Development Direction - The company is focused on enhancing customer intimacy through differentiated service offerings and leveraging the Ignite operating system for operational excellence [7][14] - Agilent aims to capture opportunities from improving end markets, innovative new products, and a multi-pronged replacement cycle [21] - The company is maintaining its expected core growth range of 4%-6% for the full year, with EPS guidance between $5.90 and $6.04 [21][30] Management's Comments on Operating Environment and Future Outlook - Management noted a solid start to the year, with underlying momentum in key markets and expectations for continued growth driven by instrument replacement cycles [16][21] - The company anticipates improved earnings growth through the remainder of the year, supported by increasing volumes and easier tariff comparisons [27] - Management expressed confidence in the ability to navigate the evolving tariff situation and maintain operational resilience [48] Other Important Information - The company experienced a $10 million revenue impact from a winter storm in the U.S., which has mostly been recovered [5][37] - Operating cash flow was $268 million, with investments in CapEx of $93 million and share repurchases of $152 million during the quarter [27] Q&A Session Summary Question: Impact of the snowstorm and expectations for catch-up - Management confirmed the $10 million revenue impact from the snowstorm has mostly been recovered, with a modest impact on margins [35][37] Question: Margin improvement cadence - The second quarter is expected to show a 50 basis point improvement in margins driven by pricing, volume, and Ignite savings [38][39] Question: Drivers for back half growth - Management highlighted strong underlying momentum in pharma and advanced materials as key drivers for growth in the second half [41][42] Question: Tariff assumptions post-Supreme Court ruling - Management stated that current guidance remains unchanged despite the dynamic tariff situation, emphasizing proactive measures taken to mitigate impacts [45][48] Question: Demand trends in capital equipment - Management reported steady demand with no significant deterioration, attributing strong performance to improved CapEx conditions [51][53] Question: M&A environment and appetite - Management expressed a deliberate approach to M&A, focusing on strategic fits without needing transformative deals to achieve growth ambitions [54][55] Question: Performance in the LDG segment - Management noted challenges in the LDG segment due to weather and academic market softness, but expressed optimism for future improvements [58][60]

Core Insights - Waters Corporation has launched next-generation 1 mm I.D. liquid chromatography (LC) columns featuring MaxPeak Premier Technology, which enhances sensitivity while reducing sample and solvent usage significantly [1][2] Group 1: Product Features - The new microflow LC columns reduce solvent consumption by up to 4 times compared to 2.1 mm I.D. columns, aiding laboratories in achieving sustainability goals and lowering operating costs [1] - These columns utilize up to 75% less sample than 2.1 mm I.D. columns, conserving valuable materials in fields like cell and gene therapy [1] - The sensitivity of the new columns is up to 2 times higher than that of stainless steel microflow columns, improving detection and quantitation limits across various applications [1] Group 2: Technological Advancements - The MaxPeak High Performance Surface (HPS) Technology minimizes nonspecific adsorption and enhances recovery for small molecules, peptides, and oligonucleotides [1] - The new columns provide sharper peaks, enhanced peak capacity, and reduced peak tailing, ensuring highly reproducible performance from the first injection [1] - Transitioning from 2.1 mm I.D. analytical-scale LC columns to these microflow formats allows for equivalent or improved sensitivity while using only one-quarter of the solvent and sample [1] Group 3: Market Impact - The introduction of these columns is expected to accelerate and simplify the development of life-changing therapies in high-throughput pharmaceutical and biopharmaceutical laboratories [1] - The new product will be available globally starting February 17, 2026, with immediate shipment [1]

Core Viewpoint - Waters Corporation's stock is trading lower following the release of its fourth-quarter 2025 financial results and fiscal 2026 guidance [1] Fourth Quarter Earnings Snapshot - The company reported quarterly sales of $932.36 million, a 7% increase as reported and 6% in constant currency, surpassing the consensus estimate of $928.09 million [2] - Sales in the academic and government market decreased by 2% as reported and 3% in constant currency [2] - Adjusted earnings were $4.53 per share, exceeding the consensus of $4.51 [2] Sales Performance - Instrument system sales increased by 3% as reported and in constant currency [3] - Recurring revenues, which include service and precision chemistries, rose by 10% as reported and 9% in constant currency [3] - Geographically, sales in Asia increased by 4% as reported and 11% in constant currency, while sales in the Americas rose by 4% as reported and in constant currency, and sales in Europe increased by 13% as reported and 4% in constant currency [3] Fiscal 2026 Guidance - The company anticipates continued momentum into 2026, driven by a multi-year instrument replacement cycle and innovation [4] - Initial guidance for 2026 indicates a combined company sales growth of 5.3% at the midpoint, with potential for outperformance [5] - Expected adjusted earnings for Q1 2026 are projected at $2.25-$2.35 per share, compared to the consensus of $2.52, with sales between $1.198-$1.211 billion [5] - For fiscal 2026, adjusted earnings are expected to be $14.30-$14.50 per share versus the consensus of $14.29, with sales projected at $6.41 billion-$6.46 billion [6] Analyst View - Analysts note that Waters' leadership in the QA/QC market benefits from multiple sector-level and idiosyncratic tailwinds, indicating the company is in the early to middle stages of a long-overdue replacement cycle [7] - The acquisition of BD Bio/Dx is expected to significantly expand the company's total addressable market (TAM) with conservative cost synergies and achievable revenue synergies [7] - Analysts expect "New Waters" to maintain above-group growth, margins, and return on invested capital (ROIC), suggesting the company will sustain a premium multiple [8]

Financial Data and Key Metrics Changes - The company achieved high single-digit reported revenue growth and low double-digit adjusted EPS growth in the fourth quarter, with sales growing 7% on a reported basis and 6% in constant currency [6][9] - Adjusted EPS grew 10% to $4.53, while GAAP EPS was $3.77 [33][34] - For the full year, sales grew 7% on both a reported and constant currency basis, with adjusted EPS growing 11% to $13.13 [10][34] Business Line Data and Key Metrics Changes - Recurring revenue grew 9%, driven by chemistry growth, while instrument revenue grew 5%, led by high single-digit LCMS growth [9][10] - Chemistry revenue grew 12% for the full year, significantly above the historical average growth rate of 7% [12][34] - The transition to a subscription-based model for Empower reduced overall instrument growth by a low single-digit percentage for the quarter, but is expected to provide long-term recurring revenue benefits [9][10] Market Data and Key Metrics Changes - Pharma revenue grew 9%, with high single-digit growth across the Americas and Europe, and low double-digit growth in Asia [15][31] - Industrial revenue grew 6%, while academic and government declined 1% [33] - In China, the company grew 9% for the year, driven by strong performance in biotech and CDMOs [16][34] Company Strategy and Development Direction - The company completed the acquisition of BD's Biosciences and Diagnostic Solutions business, aiming to strengthen its position in high-growth adjacencies and enhance operational execution [6][19] - The strategic roadmap laid out five years ago continues to advance, with a focus on innovation and commercial execution [8][10] - The company plans to expand its idiosyncratic growth driver framework from three to five drivers, adding biologics and informatics to the existing drivers [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver strong growth in 2026, with a blended year-over-year revenue growth of approximately 5.3% at the midpoint of the combined company [29][38] - The company expects to realize approximately $50 million in revenue synergies in 2026, reflecting initial contributions from commercial excellence initiatives [38][39] - Management highlighted the importance of improving operational execution and pricing discipline to enhance revenue and profitability [48][58] Other Important Information - The company expects to achieve approximately $55 million of adjusted EBIT from cost synergies in 2026 [25][39] - Free cash flow totaled $677 million for the full year, with a net debt position of $820 million at the end of the year [36][39] Q&A Session Summary Question: Insights on BD results and path to recovery - Management acknowledged several issues that emerged in Q4 impacting growth, but emphasized that these will now be present in a lower baseline for 2026, allowing for potential upside [45][47] Question: Impact of Empower transition on instruments - Management noted that the transition to subscription has created a low single-digit headwind to overall instrument numbers, but expressed confidence in the strong performance of LCMS and the overall instrument funnel [46][52] Question: Full year guidance and deceleration - Management explained that the guidance reflects prudence and incorporates assumptions about various market segments, including academic and government, and the impact of the Empower transition [55][56] Question: Update on pro forma leverage and interest expense - Management indicated that net debt is expected to be around 2.4x net debt to EBITDA, with plans to reduce it below 2 times within 18 months [63][64] Question: Synergy targets and operational execution - Management confirmed that they are on track to deliver the commitments made during the deal announcement, with a focus on identifying opportunities for cost synergies [67][70]